Core Points - Ekso Bionics Holdings, Inc. has entered into a definitive agreement for the purchase and sale of 769,490 shares of common stock at a price of $4.81 per share, expected to close around October 30, 2025 [1] - The gross proceeds from this offering are anticipated to be $3.7 million, which will be used for general corporate purposes including research and development, administrative costs, and working capital needs [3] - The shares are being offered under a "shelf" registration statement previously filed with the SEC, and the offering will be conducted via a prospectus [4] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [6] - The company focuses on improving health and quality of life through advanced robotics, and is recognized for its unique technologies that assist individuals with paralysis and enhance capabilities in various job sites [6] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [6]

Core Viewpoint - Ekso Bionics Holdings, Inc. is set to release its financial and business results for Q2 2025 on July 28, 2025, with a conference call scheduled to discuss these results and recent developments [1]. Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [3]. - The company focuses on improving health and quality of life through advanced robotics that enhance, amplify, and restore human function [3]. - Ekso Bionics is unique in offering technologies that assist individuals with paralysis to stand and walk, as well as enhancing capabilities in various job sites globally [3]. - The company is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq Capital Market under the symbol "EKSO" [3].

Core Points - Ekso Bionics Holdings, Inc. has updated the effective date of its reverse stock split from May 27, 2025, to June 2, 2025, at a ratio of 1-for-15 [1] - The number of outstanding shares will decrease from approximately 35.5 million to about 2.4 million post-split [2] - The reverse stock split was approved by stockholders to raise the per share trading price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 for ten consecutive trading days [3] Summary by Sections Reverse Stock Split Details - The reverse stock split will not result in fractional shares; any fractional shares will be rounded up to the next whole share [4] - All issued and outstanding shares will be affected, reducing the number of shares issuable upon the exercise of stock options and increasing respective exercise prices [5] Stockholder Information - Stockholders holding shares electronically will not need to take action as their shares will be automatically adjusted [6] - Shareholders with physical certificates can contact VStock Transfer, LLC for information on exchanging their certificates [6] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]

Core Insights - Ekso Bionics Holdings, Inc. is set to release its financial and business results for Q1 2025 on May 5, 2025, after market close [1] - A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments [1] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in both medical and industrial applications [3] - The company focuses on improving health and quality of life through advanced robotics that restore and amplify human function [3] - Ekso Bionics is unique in offering technologies that assist individuals with paralysis to stand and walk, as well as enhancing capabilities in various job sites globally [3] - The company is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [3]